Swiss pharma giant Novartis (NOVN: VX) has reported an impressive second quarter 2024, with net sales increasing by 11% and core operating income rising by 19% to reach $5 billion.
With growth primarily driven by higher net sales, core earnings per share (EPS) rose 21% to $1.97.
Recent periods have seen Novartis make significant strategic moves, including a collaboration with Voyager Therapeutics (Nasdaq: VYGR).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze